Physician profile
Nicholas Ahn
NPI 1376983346
$3,831.43
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.48 · 2023: $1,368 · 2024: $2,228 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,810.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $485.02 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $467.76 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $396.73 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $370.38 | 2023-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $328.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $322.92 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $224.34 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $221.65 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $173.75 | 2023-2024 | Veozah, Myrbetriq |
| Lundbeck LLC | $164.80 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.53 | 2023-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $116.11 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.55 | 2023-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $59.08 | 2024 | |
| Amgen INC. | $52.08 | 2023-2024 | Evenity, Prolia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.85 | 2023-2024 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $40.86 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Shield Therapeutics INC | $37.76 | 2024 | |
| Verona Pharma, INC. | $23.90 | 2025 | Ohtuvayre |
| Dexcom, INC. | $22.91 | 2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $18.64 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.64 | 2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $16.24 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $12.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.